全球癫痫治疗市场现状 – 行业趋势及 2030 年预测

癫痫持续状态治疗市场分析和规模

中低收入国家的癫痫发病率较高，这推动了高度发达国家对癫痫治疗的需求。根据癫痫基金会的数据，只有大约 25% 的癫痫持续状态患者会患上癫痫，而且大多数病例发生在 15 岁以下的儿童和 40 岁以上的成年人身上。癫痫持续状态有多种并发症，范围从无并发症到死亡。

Data Bridge Market Research 分析了 2023-2030 年预测期内癫痫持续状态治疗市场的增长率。在上述预测期内，癫痫持续状态治疗市场的预期复合年增长率趋于 5% 左右。2022 年市场价值为 12.1 亿美元，到 2030 年将增长至 18 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

癫痫持续状态治疗市场范围和细分

Market Definition

A status epileptic is a type of condition that is characterized by a seizure which involves abnormal electrical activity in the brain that can affect both mind and body. This problems can lead to have a seizure. The major symptoms that are related with status epileptics includes high fever, abnormal sodium or blood sugar levels, brain infections, and head injuries. Usually, in this condition, a seizure lasts for more than 5 minutes. The stroke, imbalance of blood sugar levels, drinking too much alcohol can simply leads to status epileptics disorders.

Status Epilepticus Treatment Market Dynamics

Drivers

• Increasing Incidence of Neurological Disorders

High occurrence of epilepsy and growing incidence of neurological disorder are anticipated to increase the demand for status epilepticus treatment, that is expected to drive the market growth during the forecast period. For instance, in June 2019, according to the World Health Organization (WHO), status epilepticus is a chronic, non-communicable central nervous system disease which affects more than 50 million individuals globally. Additionally, seizure recurrence is caused by abnormal brain activity. This boosts the market growth.

• Growing Number of Drug Developments

Developing potential drugs in pipeline is expected to drive the market during the forecast period. For instance, in October 2020, Marinus Pharmaceuticals initiated randomized clinical trial for drug Ganaxolone. This study assessed the effectiveness and safety of IV ganaxolone, for treating patients suffering from status epilepticus. Marinus Pharmaceuticals is about to begin patient enrollment in the drug ganaxolone Phase III RAISE research study.

Opportunities

• Rising Drug Approvals from Authorized Organizations     

Growing approvals for status epilepticus treatment is estimated to boost the market growth during the forecast period. For instance, in April 2018, the U.S. FDA granted ZENEO (Midazolam) orphan drug designation to Crossject's treatment for status epilepticus. ZENEO is a pre-filled, single use device which can deliver a medical formulation through the skin in only about 50 milliseconds. The injection parameters of the device may be tailored to the dose, injection route of the medication formulation, and viscosity. Additionally, as per Crossject, ZENEO Midazolam allows for the fast treatment of epileptic seizures, with an average effect time of 1.2 minutes.

• Increased Government Initiatives and Funding

There have been increasing funding between different organizations that can lead to the growth of the market. For instance, in March 2021, American Epilepsy Society granted fund for prolonged epilepsy up to US$ 50,000 and are estimated to support the establishment of national or worldwide multicenter research initiatives. Each award will offer funding for organisational planning sessions, infrastructure development, or pilot studies, which allows the research programme to compete for future investment.

Restraints/Challenges

• High Cost of Treatment

The amplified expenditure that is required for the diverse treatment processes inhibit the market growth. Several market players make huge investments in manufacturing new and advanced treatment procedures to faster the recovery process, and in return, the cost is increased.

This status epilepticus treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the status epilepticus treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Status Epilepticus Treatment Market Scope

The status epilepticus treatment market is segmented on the basis of types, condition, drug, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Conclusive Epilepticus
• Non-conclusive Epilepticus

Condition

• Epilepsy Drug Resistant
• Intractable Epilepsy
• Others

Drug

• Ganaxolone
• Diazepam
• Fosphenytoin
• Valproate
• Phenobarbital
• Phenytoin
• Others

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Status Epilepticus Treatment Market Regional Analysis/Insights

The status epilepticus treatment market is analyzed and market size insights and trends are provided by types, condition, drug, distribution channel and end-user as referenced above.

癫痫持续状态治疗市场报告涉及的主要国家 有：北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

北美占据市场主导地位，因为这里有几家主要的产品制造商，并且研发活动不断增加。

由于癫痫持续状态治疗市场的新研究和发展的增加，亚太地区在未来几年预计将实现增长。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。 

竞争格局和全球地位癫痫治疗市场份额分析

癫痫持续状态治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对癫痫持续状态治疗市场的关注有关

癫痫持续状态治疗市场的主要参与者包括：

• LivaNova PLC（英国）
• 葛兰素史克公司（英国）
• 卫材株式会社（日本）
• 辉瑞公司（美国）
• 美敦力（爱尔兰）
• UCB SA（比利时）
• NeuroPace, Inc（美国）
• Jazz Pharmaceuticals, Inc（英国）
• 诺华公司（瑞士）
• 强生服务公司 (印度)
• 雅培（美国）
• Sage Therapeutics, Inc（美国）
• Marinus Pharmaceuticals, Inc.（美国）
• H. Lundbeck A/S（丹麦）

SKU-56841